Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 2021

Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London

View article

Richmond Pharmacology supports Codiak BioSciences in the development of a new medicine to help patients with cutaneous T cell lymphoma.

February 2021

Richmond Pharmacology were pleased to provide our sponsor, Codiak BioSciences, with positive results of its exosome therapeutic exoIL-12.

View article

Contributing to our community in 2020

December 2020

Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.

View article

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 2020

Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.

View article

Marking a milestone for gene editing

November 2020

We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001

View article

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 2020

Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)

View article

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

News

Stay up to date with the latest activity at Richmond Pharmacology

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

Richmond Pharmacology supports Codiak BioSciences in the development of a new medicine to help patients with cutaneous T cell lymphoma.

Contributing to our community in 2020

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

Marking a milestone for gene editing

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

主要メンバー紹介

リッチモンドでのキャリア

動画紹介

Richmond Strengthens ESG Commitment Through Sustainability Accelerator Programme

Trial That Could Revolutionise Cardiac Safety Studies – Research Consortium Calls For Others To Join

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

私たちについて

ナレッジベース

ソーシャルメディア